FDA Panel Backs Epitalon, Rejects Emideltide for Compounding Pharmacies

<WASHINGTON — A Food and Drug Administration advisory panel recommended on Friday that compounding pharmacies be allowed to manufacture the peptide epitalon, but narrowly voted to recommend against manufacturing emideltide. The votes, which followed the panel’s decision on Thursday to recommend allowing pharmacies to make four other peptides, bring health secretary Robert F. Kennedy, Jr. one step closer to his mission of making these unapproved compounds more available for Americans. Peptides, which are short-chain amino acids, have become increasingly popular in the U.S., driven by endorsements from social media influencers. Read the rest…>

• An FDA advisory panel recommended allowing compounding pharmacies to manufacture the peptide epitalon on Friday.
• The same panel voted narrowly to recommend against the compounding of emideltide during the proceedings in Washington.

Regulatory Division Over Compounded Peptides

The votes concluded a two-day evaluation by the federal advisory panel. On Thursday, the panel recommended permitting compounding pharmacies to manufacture four other peptides.

Peptides consist of short-chain amino acids that function as signaling molecules within human physiology. Their rising popularity across the United States coincides with widespread visibility on social media channels.

Policy Implications for Unapproved Compounds

The panel’s recommendations bring Health Secretary Robert F.

Navigating Evolving Federal Oversight

*Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.*